Thanks for re-posting the PIM designation for DCVax-L, pgsd. Your post is why I included other gliomas in my list of possible approvals. I actually don't know if DCVax-L works on lower forms of brain cancer, but I am pretty certain that Dr. Liau has done small trials at UCLA with DCVax, I just haven't kept up with them.
I believe that NWBO has intended to go for the recurrent GBM since they wrote their statistical analysis plan in 2020. For that reason, I would dismiss the idea that the added pages were for rGBM for that reason. Since rGBM was in the SAP and did so well, I would argue they had to include it in the application.
BTW, (and forgive me if I sound like Maverick1) but I have believed and I posted, I think, that they would go for rGBM since 2015 or so when the company created a secondary trial for patients who didn't make it into the main trial. They have been capturing data from everyone who received their treatment, whether nGBM or rGBM, since they began this effort in 2007. Very forward thinking this management. That's why I support them!
Bullish
Market Data 
Markets 
AI
